chugai-JPM 2026.pdf

1、President&CEOOsamu Okuda,PhDJP Morgan Healthcare Conference 2026Company PresentationCHUGAI PHARMACEUTICAL CO.,LTD.14 January 2026This presentation may include forward-looking statements pertaining to the business and prospects of Chugai Pharmaceutical Co.,Ltd.(the“Company”).These statements reflect

2、the Companys current analysis of existing information and trends.Actual results may differ from expectations based on risks and uncertainties that may affect the Companys businesses.Chugai is in a quiet period until January 29,2026,when 2025 financial results will be announced.Chugai will not commen

3、t on undisclosed financial results.Information regarding pharmaceuticals(including products under development)is included in this presentation,but is not intended as advertising or medical advice.Important Reminder2Chugai Pharmaceutical Who we are3No.1market cap in Japanese pharma industrymarket cap

4、 in global pharma industry7.5US$BFDA Breakthrough Therapy DesignationsRevenue(2024 core results)9globally launched Chugai drugs created since 2002 Roche strategic alliance47.5%Operating Profit to Revenue Ratio(2024 core results)7An R&D-oriented Japanese pharma companyFocused on unique science and te

5、chnologiesSmall molecules AntibodiesMacrocyclic peptides(Mid-size molecules)#1in domestic sales*with strengths in oncology,immunology,ophthalmology,hematology,and neurologyStrong sales performance in Japan“active”partnership with academia and companies worldwide to drive open innovation and enhance

6、R&D capabilities60+Accelerating partnerships globally No.16Note:Market cap and exchange rates as of end of December 2025,*Sales by a promoting company basis in 2024,IQVIA top-line market data Global development,value generation and sales acceleration through out-licensing to Roche4Exclusive rights i